Last Updated on October 17, 2024 by The Health Master
Expensive Drugs in the World
In this article, we will delve into the realm of pharmaceuticals, unveiling the staggering costs associated with some of the most expensive drugs globally.
From rare diseases to groundbreaking gene therapies, the pharmaceutical industry has witnessed the development of drugs that come with an extraordinary price tag.
20. Daraprim: Battling Severe Parasitic Infections
Cost: $284,424
Company: Vyera Pharmaceuticals
Daraprim takes the 20th spot on our list, prescribed to treat severe parasitic infections like toxoplasmosis.
Learn how this medication plays a crucial role in preventing and managing infections, especially in individuals with weakened immune systems.
19. Takhzyro: A Pricey Shield Against Hereditary Angioedema
Cost: $461,611
Company: Takeda Pharmaceuticals
At number 19, Takhzyro is a medication designed to prevent hereditary angioedema attacks.
Dive into the details of this drug and understand why it comes with a hefty price, addressing the rarity of the disease it aims to combat.
18. Juxtapid: Managing Cholesterol Levels
Cost: $536,568
Company: Aegerion Pharmaceuticals
Juxtapid, at the 18th position, is enlisted for its role in reducing cholesterol levels.
Explore how this drug, in combination with other treatments, targets specific conditions, making it a costly but effective solution.
17. Cinryze: Tackling Hereditary Angioedema Through Synthetics
Cost: $548,563
Company: Shire plc
Cinryze secures the 17th spot as a synthetic form of a blood protein, crucial in regulating swelling.
Understand the significance of this drug in preventing and treating hereditary angioedema, shedding light on the complexity of its production.
16. Oxervate: A Ray of Hope for Neurotrophic Keratitis
Cost: $582,000
Company: Dompe
Oxervate, categorized as an ‘orphan medicine,’ targets neurotrophic keratitis. Learn about the challenges faced by those with this eye condition and how Oxervate strives to make a difference in the lives of affected adults.
15. Mavenclad: Managing Multiple Sclerosis with Precision
Cost: $644,760
Company: Merck Global
Securing the 15th position, Mavenclad is a vital player in managing relapsing multiple sclerosis in adults.
Delve into the article to understand how this medication stands out in its efficacy, offering relief when conventional treatments fall short.
14. Actimmune: Guarding Against Serious Infections
Cost: $660,024
Company: Horizon Pharma
At number 14, Actimmune, crafted from human proteins, plays a crucial role in defending the body against serious infections.
Explore its uses, especially in individuals with chronic granulomatous disease, and understand why it is a significant investment in healthcare.
13. Ravicti: A Specialized Solution for Urea Cycle Disorders
Cost: $695,970
Company: Horizon Therapeutics
Ravicti, designated as an ‘orphan medicine,’ steps in to address urea cycle disorders that elude dietary changes.
Uncover the intricacies of this drug, prescribed for both adults and children, highlighting its role in managing rare genetic conditions.
12. Blincyto: Targeting Rare Cases of Acute Lymphoblastic Leukemia
Cost: $754,720
Company: Amgen, Inc
Taking the 12th position, Blincyto is a beacon of hope for those with B-precursor acute lymphoblastic leukemia.
Delve into its uses, especially in relapsed or refractory cases, and understand why it earns its status as an ‘orphan medicine.’
11. Brineura: Navigating the Challenges of Neuronal Ceroid Lipofuscinosis Type 2
Cost: $755,898
Company: BioMarin Pharmaceuticals
Brineura, designed to tackle CLN2 disease, earns its place on our list as an ‘orphan medicine.’
Explore the unique challenges posed by neuronal ceroid lipofuscinosis type 2 and how Brineura stands out as a solution.
10. Folotyn: Fighting T-cell Lymphoma with Precision
Cost: $842,585
Company: Acrotech Biopharma
Securing the 10th spot, Folotyn emerges as a standalone treatment for T-cell lymphoma.
Dive into the article to understand its significance in cases of relapsed T-cell lymphoma and when other medications prove ineffective.
9. Luxturna: Illuminating the Darkness of Inherited Retinal Dystrophy
Cost: $850,000
Company: Spark Therapeutics
At number 9, Luxturna addresses vision loss resulting from inherited retinal dystrophy.
Uncover why this drug, labeled an orphan medicine, is a ray of hope for those grappling with retinitis pigmentosa and Leber’s congenital amaurosis.
8. Kimmtrak: A Lifeline for Uveal Melanoma Patients
Cost: $975,520
Company: Immunocore
Kimmtrak takes the 8th position, offering a lifeline to adults with uveal melanoma.
Explore the intricacies of this medication, recognized as an ‘orphan medicine,’ and understand why its cost aligns with the rarity of the disease it targets.
7. Danyelza: Battling High-Risk Neuroblastoma
Cost: $1.01 million
Company: Y-mAbs Therapeutics
Securing the 7th spot, Danyelza is a powerful drug in the fight against high-risk neuroblastoma.
Dive into the article to understand its unique approach, administered alongside granulocyte-macrophage colony-stimulating factor (GM-CSF).
6. Zokinvy: Reducing Risks in Hutchinson-Gilford Progeria Syndrome
Cost: $1.07 million
Company: Eiger BioPharmaceuticals
Zokinvy, approved in November 2020, takes the 6th position, offering hope to those with Hutchinson-Gilford Progeria Syndrome.
Explore how this drug reduces the risk of death and addresses progeroid laminopathies.
5. Myalept: Navigating Lipodystrophy with Precision
Cost: $1.26 million
Company: Chiesi Farmaceutici
Securing the 5th spot, Myalept plays a vital role in addressing lipodystrophy.
Dive into the article to understand how this drug, approved in 2014, stands as the sole treatment for leptin deficiency, justifying its high cost.
4. Zolgensma: A Genetic Breakthrough in Spinal Muscular Atrophy
Cost: $2.25 million
Company: Novartis
Zolgensma, a single-dose treatment for spinal muscular atrophy, claims the 4th spot.
Explore the groundbreaking approach of this gene therapy and its role in halting the progression of SMA in children under the age of 2.
3. Zynteglo: Transforming Lives Through Beta-Thalassemia Treatment
Cost: $2.8 million
Company: Bluebird Bio
Securing the 3rd position, Zynteglo stands out as a gene therapy transforming lives affected by beta-thalassemia.
Delve into the article to understand how this therapy, approved in 2022, utilizes hematopoietic stem cells for effective treatment.
2. Skysona: A Single-Dose Gene Therapy for CALD
Cost: $3 million
Company: Bluebird Bio
Skysona takes the 2nd position, emerging as a single-dose gene therapy for cerebral adrenoleukodystrophy (CALD).
Explore how this groundbreaking therapy addresses the challenges of genetic mutations in the ABCD1 gene, specifically in boys.
1. Hemgenix: Confronting Hemophilia B at a High Cost
Cost: $3.5 million
Company: CSL Behring
At the top of the list, Hemgenix takes the spotlight for its role in treating moderate to severe hemophilia B.
Understand the significance of this drug, recognized as an ‘orphan medicine,’ and its impact on those grappling with this bleeding disorder.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
The Need for Parallel Drug Approval in India: OPPI’s Urgent Plea
National Human Rights Commission’s Inquiry into Medicines Standards
India’s First Child-Friendly Chemotherapy Drug Developed
USFDA approval granted for Posaconazole Injection
NPPA Recommends Retail Prices for Anti Diabetes Drug Combinations
USFDA approval granted for Loteprednol Etabonate Ophthalmic Suspension
Income Tax demand notice for Rs 284.58 Cr to Zydus Lifesciences arm
Risks of OTC Cough Syrup for Children Below 4 Years
